KOSDAQBiotech & Pharma340570

T&L

₩27,300▲ 7.27%2026-11-18 close
Market Cap
₩438.7B
Turnover
₩3.3B
Volume
120K
Shares out.
16.1M
PER
4.0×
PBR
—
EPS
₩6,442
Dividend Yield
—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Prices as of the 2026-11-18 close

01

Report overview

U.S. export recovery lifts T&L's quarterly profit

T&L's operating profit recovered from KRW 4.02 billion in Q4 2025 to KRW 25 billion in Q2 2026, a rebound tied to the recovery in U.S. exports.

  1. 1

    Wound-dressing products are the core business with a high export share, and the U.S. distributor C&D is a key channel for wound-dressing exports.

  2. 2

    2024 was the largest year in 2022-2025, with revenue of KRW 174.9 billion and operating profit of KRW 57 billion. In 2025, revenue fell 6.1% to KRW 164.2 billion and operating profit fell 18.6% to KRW 46.4 billion.

  3. 3

    Quarterly operating profit rose to KRW 18.3 billion in Q1 2026, KRW 25 billion in Q2 and KRW 21.7 billion in Q3, and media reports put the Q2 operating margin at 44.6%.

  4. 4

    Exchange rates and seasonality drive quarterly swings. Export sales are booked at the exchange rate on the shipping date, so currency moves feed directly into revenue.

  5. 5

    Sangsangin Securities maintained its BUY rating and presented a target price of KRW 93,000 in a report dated July 27, 2026.

02

Business structure

T&L is a medical-materials company whose main product is wound-care dressings. KB Securities' March 2022 report listed wound-care products at 81.7%, orthopedic fixation products at 11.8% and high-function materials at 6.5%.

The same brokerage's May 2023 report showed wound dressings at 85.9%, orthopedic fixation at 8.2% and other products at 5.8%, so the wound-dressing weight grew between 2022 and 2023. Hydrocolloid dressings are the core line, and Hana Securities' May 2026 product-mix table showed their share ranging from 71% to 83%.

Microneedle patches and orthopedic fixation products follow. Sales are export-driven, and exports of wound dressings through the U.S. distributor C&D are the key channel. In Europe, a channel through Germany's Stryze Group was described in a 2022 report.

U.S. demand depends on event volumes tied to hero-cosmetics products, which concentrate in Q4, so orders are placed in advance in Q2, according to Hana Securities.

In its value-up plan disclosed on March 27, 2026, the company listed portfolio expansion, customer and market diversification, and stronger R&D and overseas sales. Brokers describe overseas distribution channels and production efficiency as its points of differentiation.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩40.7B₩12.1B29.8%
2025Q4₩33.4B₩4B12.0%
2026Q1₩45.1B₩18.3B40.5%
2026Q2₩56B₩25B44.6%
2026Q3₩52.5B₩21.7B41.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩81.6B₩24.3B₩21.1B29.8%19.9%10.3%
2023₩115.5B₩30.8B₩27.4B26.7%21.2%9.7%
2024₩174.9B₩57B₩46.4B32.6%27.1%15.0%
2025₩164.2B₩46.4B₩38.1B28.2%18.9%7.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual results moved from KRW 81.6 billion in revenue and KRW 24.3 billion in operating profit in 2022 to KRW 174.9 billion and KRW 57 billion in 2024, the largest year in 2022-2025. Revenue rose 41.5% to KRW 115.5 billion in 2023 and operating profit rose 26.9% to KRW 30.8 billion.

In 2024, revenue rose 51.5% and operating profit rose 84.7%. In 2025, revenue fell 6.1% to KRW 164.2 billion, operating profit fell 18.6% to KRW 46.4 billion, and controlling-shareholder net income fell 18.0% to KRW 38.1 billion. Operating margin was 29.8% in 2022, 26.7% in 2023, 32.6% in 2024 and 28.2% in 2025.

Sangsangin Securities said the U.S. wound-dressing inventory adjustment was completed in 2025, a factor behind the decline.

Quarterly results show a trough in Q4 2025, with revenue of KRW 33.4 billion (down 17.9% from the prior quarter), operating profit of KRW 4.02 billion (down 66.9%) and controlling-shareholder net income of KRW 3.06 billion (down 73.0%).

Q1 2026 revenue was KRW 45.1 billion, operating profit KRW 18.3 billion and controlling-shareholder net income KRW 16.4 billion. Q2 2026 revenue was KRW 56 billion, operating profit KRW 25 billion and controlling-shareholder net income KRW 19.9 billion.

Q3 2026 revenue was KRW 52.5 billion (down 6.2% from the prior quarter, up 29.2% year on year), operating profit KRW 21.7 billion (down 13.0% quarter on quarter, up 78.9% year on year) and controlling-shareholder net income KRW 12.9 billion (up 14.0% year on year).

Controlling-shareholder net income for the last four quarters totaled KRW 52.4 billion. On margins, Hana Securities said a return to two- and three-shift operations lowered fixed-cost burdens. Exchange rates matter because export sales are recorded at the rate on the shipping date.

At the end of 2025, total equity was KRW 201.2 billion, total liabilities KRW 15.9 billion and the debt ratio 7.9%.

05

Industry analysis

The wound-dressing market overlaps wound care with regeneration and cosmetic uses. T&L sells hydrocolloid products through U.S. and European distribution channels. U.S. demand depends heavily on event volumes tied to hero-cosmetics products, which Hana Securities said concentrate in Q4, making Q2 the seasonal peak.

In the cycle, the 2025 U.S. inventory adjustment was a drag, and brokers generally describe U.S. exports as normalizing in 2026. Sangsangin Securities estimated that U.S. wound-dressing exports would rise 62.9% year on year in Q2 2026.

Exchange rates affect earnings independently of the industry cycle, and Hana Securities estimated that each 10-won move in the monthly average rate shifts revenue by about KRW 100 million. On production, efficiency work and capacity expansion began in 2025, and equipment upgrades have raised line utilization. Brokers point to overseas distribution channels and production efficiency as points of differentiation.

06

Outlook

The company's most recent medium-term direction is its value-up plan disclosed on March 27, 2026. The plan covers portfolio expansion, customer and market diversification, and stronger R&D and overseas sales.

Shareholder returns also increased, with the year-end 2025 dividend confirmed at the March 2026 shareholders meeting at a higher per-share amount than the prior year. A 1-for-1 bonus issue was announced in the same year, with a new-share allotment record date of August 7, 2026.

Hana Securities said in its May 2026 report that details of a supply contract were being coordinated with the head office. Sangsangin Securities said in its July 2026 report that continued supply to global customers was the premise for earnings improvement.

Sangsangin had estimated Q2 2026 revenue at KRW 55.1 billion and operating profit at KRW 21.9 billion, while disclosed Q2 figures were KRW 56 billion and KRW 25 billion. Hana Securities projected Q3 2026 operating profit at KRW 16.4 billion, versus disclosed KRW 21.7 billion.

The next checkpoint is whether Q4 event-related demand converts into export sales. The next regular report is the 2026 annual report, where the full-year operating margin will be compared with 28.2% in 2025.

07

Valuation

PER
4.0×
PBR
—
ROE
24.2%
EPS
₩6,442
BPS
—
Dividend per share
—

Valuation reads best when earnings recovery and market capitalization are considered together. Controlling-shareholder net income for the last four quarters totaled KRW 52.4 billion, which is above the KRW 46.4 billion recorded for full-year 2024.

Sangsangin Securities described the multiple on 2026 expected earnings as low. Compared with total equity of KRW 201.2 billion at the end of 2025, market capitalization sits in a premium range above book value.

Dividends increased in the 2025 year-end settlement, and Sangsangin expects further increases to track earnings growth. A debt ratio of 7.9% is a fact about the balance sheet. How the multiple is read depends on whether earnings return to the 2024 level.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

U.S. export recovery and quarterly rebound

Sangsangin Securities and Hana Securities both described U.S. exports as normalizing or recovering in 2026 after the 2025 inventory adjustment. Operating profit rose from KRW 4.02 billion in Q4 2025 to KRW 18.3 billion in Q1 2026 and KRW 25 billion in Q2.

Q3 operating profit of KRW 21.7 billion, up 78.9% year on year, shows the recovery extended beyond a single quarter.

Production efficiency and margin improvement

Hana Securities said a return to two- and three-shift operations lowered fixed costs and raised use of the same equipment. Media reports put the Q2 operating margin at 44.6%. Sangsangin Securities said higher sales and a stronger exchange rate lowered the cost ratio, producing a sizable operating leverage effect.

Shareholder returns and a broker target price

The company raised its year-end 2025 dividend from the prior year and announced a 1-for-1 bonus issue. The target price of KRW 93,000, presented alongside a maintained BUY rating, is Sangsangin Securities' own figure as of July 27, 2026.

09

Bear factors

Exchange-rate swings feed directly into revenue

Export sales are recorded at the exchange rate on the shipping date, so currency moves hit revenue directly. Hana Securities estimated that each 10-won move in the monthly average rate shifts revenue by about KRW 100 million.

The won-dollar rate fell sharply after July 2026, which Hana Securities said would weigh on export-heavy revenue.

Seasonality and the Q4 2025 low

Q2 is the seasonal peak, so Q3 revenue and operating profit fell from Q2 levels. Operating profit hit a quarterly low of KRW 4.02 billion in Q4 2025, and concentrated event demand adds to quarterly volatility. Hana Securities expected Q3 to show year-on-year growth in an off-season rather than repeat Q2's pace.

Channel concentration and inventory cycles

Because exports through U.S. distributor C&D are a key channel, distributor-side inventory adjustments affect shipments directly. The 2025 inventory adjustment reduced U.S. wound-dressing exports.

Sangsangin Securities estimated a 62.9% increase in these exports for Q2 2026, and a miss against that estimate would change the pace of recovery.

10

Risk factors

Currency

The won-dollar rate directly affects export revenue, and booking exports at the shipping-date rate amplifies quarterly swings. The sharp rate decline noted for Q3 2026 was cited as a revenue burden. The same shipment yields different won revenue depending on the rate's direction.

Channel concentration

Heavy reliance on a U.S. distributor means inventory adjustments can cut exports sharply. The 2025 U.S. inventory adjustment already reduced revenue and profit. A 2022 report also described European sales as running through a small number of distribution partners, such as Stryze Group.

Cost and labor

Two- and three-shift production is sensitive to labor and logistics costs. A 2022 report flagged rising labor and logistics costs as a margin risk, and a 2023 report cited year-end bonus payments as another source of labor-cost pressure. Whether efficiency gains and higher utilization offset these costs remains to be checked.

11

What to watch next

  1. December 2026

    U.S. year-end event demand concentrates in Q4, so this is the point to check whether Q2 advance orders convert into Q4 exports.

  2. End of December 2026

    Whether the sharp won-dollar decline after July 2026 persists to year-end will shape Q4 won-denominated revenue.

  3. Early 2027 (typical timing for preliminary annual results)

    This is where Q4 2026 revenue and operating profit can be compared with the Q4 2025 trough of KRW 4.02 billion. Preliminary results precede the periodic report and should be read separately from disclosed figures.

  4. End of March 2027

    The 2026 annual report filing deadline is the next periodic checkpoint, where full-year revenue, operating profit and margin can be compared with the 2025 operating margin of 28.2%.

12

Overall view

T&L is a wound-dressing company with a high export share. Results peaked in 2024, with revenue of KRW 174.9 billion and operating profit of KRW 57 billion, before declining in 2025.

The Q4 2025 operating profit of KRW 4.02 billion marked the quarterly low, followed by KRW 18.3 billion in Q1 2026, KRW 25 billion in Q2 and KRW 21.7 billion in Q3. Brokers attribute the recovery to the end of the U.S. inventory adjustment, export normalization and cost-ratio gains from production efficiency.

On the other side, the direct pass-through of exchange rates to revenue, quarterly volatility from the Q2 peak and reliance on a U.S. distributor remain weaknesses.

Sangsangin Securities presented a target price of KRW 93,000 on July 27, 2026, while Hana Securities' September 2026 report presented no target price or rating. On the balance sheet, the 7.9% debt ratio and KRW 201.2 billion in total equity at the end of 2025 are disclosed facts.

The next checkpoints are whether Q4 2026 exports keep recovering alongside year-end event demand and whether the 2026 annual operating margin exceeds 28.2% for 2025.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. file.hanaw.com
  3. ant.wiki
  4. ssl.pstatic.net
  5. m.thinkpool.com
  6. alphasquare.co.kr
  7. moneyrecipe.blog
  8. pharm.edaily.co.kr
  9. rdata.kbsec.com
  10. rdata.kbsec.com
  11. investing.com
  12. pinpointnews.co.kr
  13. hibulls.com
  14. investing.com
  15. pharm.edaily.co.kr
  16. m.thinkpool.com
  17. newspim.com
  18. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis